About this raise
Med-X, with a pre-money valuation of $102 million, is raising funds on Dalmore via Regulation A+. The company has developed many all-natural and plant-based brands that are replacing chemicals to solve everyday issues. The products are sold through major retail and healthcare distributors. The flagship product lines of Med-X include Nature-Cide and Thermal-Aid. Med-X is led by Dr. David Toomey and Matthew Mills and was founded in 2014.
Investment Overview
Invested $3,936,422 :
Deal Terms
Company & Team
Company
- Year Founded
- 2014
- Industry
- Consumer Products, Goods & Services
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Financials
- Revenue +29% YoY
- $1,033,750
- Monthly Burn
- $254,167
-
Runway
- 3 months
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
05/27/2025 | DealMaker Securities | $50,894,025 | $1,022,943 | Equity - Common | Active | RegCF |
11/09/2023 | Dalmore Group | $102,217,405 | $3,936,422 | Equity - Common | Funded | RegA+ |
05/23/2023 | PicMii | $43,211,544 | $0 | Equity - Common | Not Funded | RegCF |
09/10/2021 | truCrowd | $88,552,772 | $15,595 | Equity - Common | Funded | RegCF |
06/27/2019 | StartEngine | - | $7,000,471 | Equity - Common | Funded | RegA+ |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.